Tango Therapeutics, Inc. (TNGX): Price and Financial Metrics
TNGX Price/Volume Stats
| Current price | $3.10 | 52-week high | $13.01 |
| Prev. close | $2.94 | 52-week low | $2.70 |
| Day low | $2.80 | Volume | 2,817,600 |
| Day high | $3.13 | Avg. volume | 1,051,141 |
| 50-day MA | $4.46 | Dividend yield | N/A |
| 200-day MA | $7.53 | Market Cap | 333.00M |
TNGX Stock Price Chart Interactive Chart >
Tango Therapeutics, Inc. (TNGX) Company Bio
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
TNGX Price Returns
| 1-mo | -14.60% |
| 3-mo | -62.65% |
| 6-mo | -69.46% |
| 1-year | -69.06% |
| 3-year | -71.69% |
| 5-year | N/A |
| YTD | -68.69% |
| 2023 | 36.55% |
| 2022 | -33.73% |
| 2021 | -4.37% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...